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Is Echocardiography
Reliable for Monitoring
the Adverse Cardiac
Effects of Chemotherapy?*
Victor Mor-Avi, PHD, Roberto M. Lang, MD
Chicago, Illinois
Very few would dispute the diagnostic value of echocardi-
ography, which has earned its place in the armamentarium
of clinical cardiology by being for decades the only nonin-
vasive imaging modality capable of providing dynamic views
of the beating human heart in real time. Most recently, this
role has been further enhanced by 3-dimensional (3D)
echocardiography, capable of providing unique realistic
views of cardiac structures, virtually in real time. It is almost
unimaginable today to make a diagnosis of almost any
cardiac pathology without ultrasound imaging. Importantly,
beyond the visual impact of these images and their contri-
bution to the understanding of normal cardiac function and
the recognition of different pathological states, the second
most valuable clinical benefit derived from echocardiogra-
phy is the ability to measure structural and functional
parameters, adding another layer to the depth of knowledge
of the pathophysiology of disease.
See page 77
However, in routine clinical practice this ability cannot be
taken for granted, because it inherently depends on the
quality of the images used for measurements. Because image
quality varies among patients, depending on a variety of
well-known factors, the reproducibility of echocardio-
graphic measurements is not uniformly excellent. Conse-
quently, the evaluation of inter-measurement variability of any
image-derived parameter has become a standard requirement
and an integral part of its validation. Usually, investigators
report intra- and inter-observer variability, determined by
repeated measurements performed on the same images by
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contents of this paper to disclose.observers blinded to the results of prior measurements. Less
frequent are reports of the more demanding assessment of
test-retest variability, on the basis of repeated image acquisition
followed by analysis of different images.
One of the rapidly evolving roles of echocardiography in
the management of cancer patients undergoing chemother-
apy is the serial evaluation of left ventricular (LV) size and
function (1–5). This is precisely the scenario in which
test-retest variability, or temporal variability, of the mea-
surement technique is crucial. This is because the premise of
serial examinations is that the technique should be suffi-
ciently reliable, such that detection of a critical change over
time would indicate a true, clinically meaningful finding
rather than reflect random measurement variability.
The study by Thavendiranathan et al. (6) in this issue of
the Journal focuses on this problem and was specifically
designed to identify the optimal echocardiographic tech-
ique for the serial evaluation of LV function in cancer patients
ndergoing chemotherapy, defined by the lowest temporal
ariability. This study included both 2-dimensional (2D) and
D echocardiographic measurements, and its results once
gain demonstrated the advantages of the 3D approach in
he context of this critically important clinical problem.
mportantly, rather than simply re-imaging and re-
easuring LV volume and ejection fraction (EF) to deter-
ine the test-retest variability, the investigators made an
dditional important step by placing their study in the
pecific context of serial evaluation of these patients over a
eriod of 1 year. To avoid drug-induced changes from being
istaken for temporal variability of the measurements, they
ppropriately included only patients with stable LV func-
ion, as defined by invariably normal global longitudinal
train. This latter parameter of myocardial deformation is
ncreasingly gaining acceptance as a sensitive index of
yocardial function on the basis of rapidly growing scien-
ific evidence (7–10).
Although it is widely agreed that in most clinical scenarios
nter-measurement variability 10% of the measured value is
cceptable, it is also well-recognized that a measurement
echnique with such a level of reproducibility is in fact
cceptable only if it is aimed at detecting changes that are
onsiderably 10%. If for example the normal value of a
ormally distributed parameter has an SD that is 2% of the
ean, values outside the 4% range would be considered
bnormal. In this case, one should critically assess the value of
he measurement technique that has inter-measurement vari-
bility as high as 10%, which is considerably greater than the
ifference that the technique is required to detect. In other
ords, one cannot rely on a technique with inter-measurement
ariability that is higher than the difference to be detected.
This limitation of measurement techniques needs to be
ritically examined, considering that most studies report
nter-measurement variability as a mean  SD of either the
bsolute difference between pairs of repeated measurements
n percentage of their mean or as the coefficient of variation,
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This means that measurement variability in individual
subjects can be as high as the reported mean measurement
variability plus its 2 SD. For example, if a technique was
found in a group of 100 patients to have variability of 5 
7%, it means that in 10 of the 100 patients the variability
was outside the 2-SD range (i.e., the technique could result
in differences larger than 5  2  7%—19% or more),
imply because of a random measurement error. Thus, it
ould be a very legitimate question to ask, “What is the
agnitude of change that this technique could detect
eliably?” In other words, when a technique is reported to be
eproducible within 5%, as determined with repeated mea-
urements, it does not automatically mean that it is capable
f reliably detecting differences 5%. Conversely, one
hould very carefully consider the confidence interval asso-
iated with the reported variability.
In the context of the cardiotoxicity of chemotherapy,
revious studies have suggested that on consecutive exami-
ations an asymptomatic decrease in LVEF of 10% to
55% or a decrease of 5% to 55%, combined with
symptoms of heart failure, might indicate dangerous effects
of the drug on the myocardium and should trigger consid-
eration of therapy modification (11). With the aforemen-
tioned logic, to be able to detect a 5% change in EF with
confidence, the measurement technique should have inter-
measurement variability of less than the sum of its reported
mean plus its 2 SD at 5%. In other words, the upper limit
of the confidence interval needs to be 5% to guarantee
that, in 90% of the patients in whom a decrease 5% in
LVEF is detected, this decrease would indeed be a mean-
ingful finding and not a measurement error.
To help us interpret their data correctly, Thavendirana-
than et al. (6) reported their findings in terms of coefficients
of variation with the corresponding confidence intervals.
The examination of data in their Online Table A reveals
that, among the 6 techniques they tested for the measure-
ment of the 3 parameters (end-systolic and end-diastolic
volume and EF), the 3D measurement of EF provided the
desired level of reproducibility—as reflected by the upper
limit of the confidence interval, which is 4.9% (i.e., just
below the 5% target). Importantly, all 4 2D techniques
showed temporal variability that was roughly twice as high.
This finding is not surprising in view of multiple recent
studies that reported increased accuracy and reproducibility
of the volumetric approach compared with the traditional
2D echocardiographic measurements (12). It is widely
accepted that this advantage stems from the fact that the 3D
measurements are not affected by foreshortened views and
do not rely on geometric modeling of the ventricular
boundaries. In addition, the software used by Thavendi-
ranathan et al. (6) allows interactive adjustments of the 3D
endocardial surface in any arbitrary plane to guarantee for
accurate volume calculation.
In summary, this study constitutes an important step
toward establishing real-time 3D echocardiography as theimaging modality of choice for the evaluation of the effects
of chemotherapy. This is because of its demonstrated
capability to detect with confidence changes in LV function
that supposedly indicate deleterious effects of chemotherapy
(i.e., a drop of 5% in LVEF combined with symptoms of
heart failure). It is of note that the findings of Thavendi-
ranathan et al. also (6) indicate that 2D echocardiographic
techniques can be reasonably trusted in the detection of a
10% difference in LVEF and used as an indication of
cardiotoxicity in the absence of symptoms. This is because
the upper limit of the confidence interval of these measure-
ments is roughly 10% (range 9.1 to 11.8). This finding is of
particular importance for laboratories that do not yet have
access to or the expertise with 3D echocardiography.
Of course, one should remember that these are findings
of a single study, albeit with a reasonable sample size. Future
studies will show whether the findings reported here can
indeed be extrapolated onto the general population of cancer
patients undergoing chemotherapy. This question will need
to be answered in future multi-center studies. However, the
major importance of this study is that it provides the
critically needed scientific evidence to support routine clin-
ical use of 3D echocardiography for the monitoring of
adverse cardiac effects of chemotherapy. In addition, the
evolving use of myocardial deformation indexes might
provide additional echocardiographic tools to assess these
effects beyond the EF.
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